Dalibor S.
- Country
- Slovakia
- Department
- #4114: Ambulancia diabetológie a porúch látkovej premeny a výživy
Research Overview
- Effect of Olpasiran on Major Cardiovascular Events in Patients with Atherosclerotic Cardiovascular Disease and Elevated Lipoprotein(a): A Randomized, Placebo-Controlled Study
- Efficacy and Safety of MET097 in Adults with Overweight or Obesity: A Phase 3, Randomized, Placebo-Controlled Trial
- Phase 3 Randomized, Placebo‑Controlled Trial Assessing Efficacy and Safety of MET097, a Long‑Acting GLP‑1 Receptor Agonist, in Overweight/Obese Adults with Type 2 Diabetes
Data & Insights
Has run more than one trial at 972 of 1552 partner sites.
Specializations
Metabolic Disorders
The investigator specializes in treating obesity and type 2 diabetes mellitus, with particular emphasis on innovative therapeutic approaches for weight management and glycemic control.
- Weight management interventions
- Diabetes treatment optimization
- Metabolic disease management
Research extends to novel therapeutic agents like orforglipron and tirzepatide for metabolic disorder treatment.
Cardiovascular Medicine
Focuses on atherosclerotic cardiovascular disease prevention and treatment, with expertise in managing complex lipid disorders and cardiovascular risk factors.
- Lipid management therapies
- Cardiovascular risk reduction
- Hypertriglyceridemia treatment
Investigates innovative approaches using compounds like inclisiran and olezarsen for cardiovascular health improvement.
Renal Medicine
Specializes in chronic kidney disease management with particular attention to complications like proteinuria and hypertension.
- Kidney disease progression
- Proteinuria management
- Renal function preservation
Explores combination therapies including baxdrostat and zibotentan for kidney disease treatment.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.